Clinical Trials
44 trialsRAINFOL-02
Genmab
FRAmework-01
Eli Lilly and Company
GLORIOSA
AbbVie
RAINFOL-02
Genmab
TroFuse-022
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
OVATION-3
Imunon
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
FLORA-5
CanariaBio Inc.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
KEYNOTE-B96
Merck Sharp & Dohme LLC
ARTISTRY-7
Mural Oncology, Inc
MIRASOL
AbbVie
ATHENA
pharmaand GmbH
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Innovent Biologics (Suzhou) Co. Ltd.
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
SORAYA
ImmunoGen, Inc.
CATCH-R
pharmaand GmbH
AL3818
Advenchen Laboratories, LLC
UP-NEXT
Mersana Therapeutics
ARIEL3
pharmaand GmbH
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
JAVELIN OVARIAN PARP100
Pfizer
IMagyn050
Hoffmann-La Roche
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
OncXerna Theraputics, Inc.
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
VITALIA
Sotio Biotech Inc.
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novartis
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
FORWARD I
ImmunoGen, Inc.
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
TRINOVA-2
Amgen
OCEANS
Genentech, Inc.
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Amgen
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Amgen
OVATURE
MEI Pharma, Inc.
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Study of Paclitaxel in Patients With Ovarian Cancer
Oasmia Pharmaceutical AB
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Eli Lilly and Company
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company